|
市場調査レポート
商品コード
1292531
上肢インプラントの世界市場規模、シェア、産業動向分析レポート素材別、タイプ別(肩、肘、手・手首)、エンドユース別(病院、クリニック、ASC')、地域別展望と予測、2023~2029年Global Upper Extremity Implants Market Size, Share & Industry Trends Analysis Report By Material, By Type (Shoulder, Elbow and Hand & Wrist), By End-use (Hospitals, Clinics and ASCs'), By Regional Outlook and Forecast, 2023 - 2029 |
||||||
|
上肢インプラントの世界市場規模、シェア、産業動向分析レポート素材別、タイプ別(肩、肘、手・手首)、エンドユース別(病院、クリニック、ASC')、地域別展望と予測、2023~2029年 |
出版日: 2023年05月31日
発行: KBV Research
ページ情報: 英文 222 Pages
納期: 即納可能
![]() |
上肢インプラントの市場規模は、2029年までに23億米ドルに達すると予測され、予測期間中にCAGR6.2%の市場成長率で上昇すると予想されています。
KBV Cardinalマトリックスで提示された分析に基づき、DePuy Synthes(Johnson &Johnson)が本市場の先行者です。2021年10月、DePuy Synthesは、小・中・大の鎖骨の外側・軸・内側骨折の治療のために、2.7mmの鎖骨プレートシステム「Variable Angle Locking Compression Plate」を発表しました。発売された製品は、鎖骨の大きさと患者の身長の相関関係を示すプレート形状を提供し、鎖骨の弓と輪郭に合わせ、鎖骨の幅広い解剖学的可変性を含んでいます。Medtronic PLC、Stryker Corporation、Zimmer Biomet Holdings, Inc.などの企業が、本市場における主要なイノベーターとして挙げられます。
市場の成長要因
スポーツ傷害の増加
特に若年層における怪我の増加の主な原因は、特定のスポーツに1年中参加することです。現在では、多くのアスリートが一つのスポーツに特化し、集中することを選択しています。そのため、今日では、わずかな筋肉のアンバランスや機能障害が、使い過ぎによる怪我につながる可能性がはるかに高くなっています。また、18歳以下のアスリートはより多くの怪我に苦しんでいます。さまざまな予防活動に取り組んでいても、それを実行に移すことは難しいのかもしれません。このように、スポーツに関連した傷害は、特に若年層で多くなっており、これが上肢インプラントの需要を押し上げ、市場拡大を支えるものと予測されます。
高齢者の増加
人口の高齢化、つまり年齢分布が高齢化することは、高所得国を中心に見られるようになりました。しかし、この動向は中低所得国において最も大きな影響を及ぼしています。例えば、日本では30歳以上の高齢者が60%を超えています。2050年には、60歳以上の人口のほとんどを低・中所得国が占めるようになると予想されています。平均寿命の延びにより、高齢化社会が進行しています。そして、高齢者は筋肉や関節に関連した合併症を起こしやすく、上肢などのインプラントが必要になる可能性があるため、市場成長を牽引すると予想されます。
市場抑制要因
インプラント手術後の合併症
すべての外科手術にはいくつかのリスクがあり、伝染性感染症の存在はこれらのリスクを悪化させる可能性があります。感染症、血液の流出、脱臼の危険性は、人工関節置換術に伴う3つの主要なリスクです。インプラントの脱臼は、インプラント周囲の筋力が低下しているとき(特に治療後3ヶ月間)に、不適切な動作で起こる可能性がある問題です。この問題を防ぐためには、特に手術後3ヶ月間は特定の動作を避けることが重要です。これは、上肢用インプラントの市場成長の妨げになると考えられます。
タイプの展望
タイプ別に見ると、市場は肩、肘、手・手首に区分されます。2022年の市場では、肩のセグメントが最も高い収益シェアを占めています。これは、スポーツ傷害、肩関節脱臼、高齢化、変形性関節症例の増加、肩関節骨折などの増加により、上肢のインプラント用製品の需要が高まっているためです。また、四肢の整形外科手術の中で、肩関節置換術は最も多い手術の一つです。
材料の展望
素材別に見ると、金属系バイオマテリアル、セラミック系バイオマテリアル、高分子系バイオマテリアル、天然系バイオマテリアルに分類されます。天然バイオマテリアルセグメントは、2022年の市場においてかなりの成長率を調達しました。天然バイオマテリアルは、外科手術に普及しています。また、このバイオマテリアルの足場や支持体は、細胞が新しい組織の構築を開始することを可能にし、予測期間においてこのセグメントの成長をもたらします。
最終用途の展望
エンドユーズ別では、病院、ASC、クリニックに分類されます。ASCセグメントは、2022年の市場において有望な成長率を集めました。これは、上肢の手術におけるASCの需要の増加、新製品の進歩の増加、FDAの承認に起因します。優れた術後疼痛管理、患者の早期退院、副作用の少なさ、全体的なコストの最小化により、ASCsカテゴリは患者にさらなるメリットを提供します。以上のような要因が、この市場セグメントの成長を促進すると予想されます。
地域別展望
地域別では、北米、欧州、アジア太平洋、LAMEAで分析されています。北米地域は、2022年の市場において最も高い収益シェアを獲得しました。これは、骨折、捻挫、歪み、脱臼や分離を含む肩の怪我の増加などの要因によります。さらに、北米における重要な参加者の存在とスポーツ傷害の増加が、地域拡大を促進しています。また、骨折、脱臼、腱鞘炎、関節炎などさまざまな病気を治療するヘルスケア施設の設立に伴い、製品へのニーズが著しく高まっており、同地域の市場成長を後押ししています。
List of Figures
The Global Upper Extremity Implants Market size is expected to reach $2.3 billion by 2029, rising at a market growth of 6.2% CAGR during the forecast period.
Natural Biomaterials is gaining popularity and growing at a faster rate because of its capacity for integrating and modifying as well as their bio-compatibility with the patient's tissue. Therefore, Natural Biomaterials registered $157.8 million revenue in 2022. According to a recent analysis of Global Burden of Disease (GBD) 2019 statistics, 1.71 billion people worldwide are affected by musculoskeletal diseases such as fractures, osteoarthritis, amputation and other injuries, and arthritis. Most affected are 441 million in high-income countries, 427 million in the WHO Western Pacific Region, and 369 million in the WHO South-East Asia Region. In addition, musculoskeletal diseases are the leading cause of YLDs, accounting for more than 149 million YLDs, or 17 percent of all YLDs globally.
The major strategies followed by the market participants are Acquisitions as the key developmental strategy in order to keep pace with the changing demands of end users. For instance, In November, 2020, Stryker acquired Wright Medical Group N.V. to innovate and reach more patients. Additionally, In May, 2023, Zimmer Biomet took over Ossis to build out their partnership and broadening Zimmer Biomet's orthopedic suite with the addition of Ossis' personalized implants. Together with this, Zimmer Biomet Holdings, Inc. acquired Embody, Inc. in February, 2023, to strengthen its growing Sports Medicine suite and supports continued business transformation.
Based on the Analysis presented in the KBV Cardinal matrix; DePuy Synthes (Johnson & Johnson) is the forerunner in the Market. In October, 2021, DePuy Synthes introduced Variable Angle Locking Compression Plate, a 2.7 mm Clavicle Plate System, for the treatment of lateral, shaft and medial fractures for small, medium and large clavicles. The launched product provides plate shapes that show the correlation between clavicle size and patient stature to match the bow and contour of the clavicle and contain a wide range of anatomic variability of the clavicle. Companies such as Medtronic PLC, Stryker Corporation and Zimmer Biomet Holdings, Inc. are some of the key innovators in Market.
Market Growth Factors
The increasing prevalence of sport injuries
The leading cause of the increase in injuries, especially in young people, is the year-round participation in a particular sport. Nowadays, many athletes opt to specialize in and focus on just one sport. So today, a slight muscle imbalance or dysfunction is far more likely to lead to an overuse injury. Also, athletes under the age of 18 are suffering more injuries, even though they engage in various preventative activities, putting it into action could be difficult. Thus, for these reasons, sports-related injuries are becoming more common, particularly in young people, which is predicted to drive up demand and support market expansion.
The growing number of older adults
Population aging, or a country's movement in age distribution toward older ages, has been seen mostly in high-income nations. However, this trend has the biggest influence in low- and middle-income countries. For instance, the population of Japan is over 60% older than the age of 30. Most people over 60 are expected to live in low- and middle-income countries by 2050. An aging population is on the rise due to increased life expectancy. And as older populations are more prone to muscle or joints related complications, which may require implants like upper extremities, implants are expected to drive the market growth.
Market Restraining Factors
Complications following implant surgery
Every surgical operation has some risks; the existence of contagious infections can make these risks worse. The danger of infection, blood effusion, and dislocation are the three main risks associated with joint replacement surgery. Dislocation of the implant is a problem that can happen during an inappropriate movement when the muscles surrounding the implant are too weak (particularly in the first three months following the treatment). Avoiding specific motions is crucial to preventing this problem, especially in the first three months following the operation. This will hinder the market growth for upper extremities implants.
Type Outlook
Based on type, the market is segmented into shoulder, elbow and hand & wrist. The shoulder segment held the highest revenue share in the market in 2022. This is due to the increase in sports injuries, shoulder dislocations, an aging population, a growth in osteoarthritis cases, and shoulder fractures, resulting in a rise in demand for products for implanting the upper extremities. In addition, shoulder replacements rank among the most common orthopedic operations for the extremities.
Material Outlook
On the basis of material, the market is divided into metallic biomaterials, ceramic biomaterials, polymeric biomaterials and natural biomaterials. The natural biomaterials segment procured a considerable growth rate in the market in 2022. Natural biomaterials have become popular in surgical operations. Also, this biomaterial's scaffolding or support enables cells to begin building new tissue, which provides the segment's growth in the forecasted period.
End-Use Outlook
By end-use, the market is classified into hospitals, ASCs' and clinics. The ASCs' segment garnered a promising growth rate in the market in 2022. This is due to increased demand for ASCs in upper-extremities procedures, increased new product advancements, and FDA approval. With excellent postoperative pain management, quick patient discharge, few side effects, and overall cost minimization, the ASCs category offers additional benefits to the patient. The above-mentioned factors are anticipated to drive the market segment's growth.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America region generated the highest revenue share in the market in 2022. This is owing to factors like the increase in shoulder injuries, including fractures, sprains, and strains, as well as dislocations and separations. In addition, the presence of important participants in North America and the rise in sports injuries are driving regional expansion. Also, the need for products has grown significantly as a result of the establishment of healthcare facilities that treat a variety of ailments, such as fractures, dislocations, tendonitis, and arthritis, which is fueling the market growth in the region.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Stryker Corporation, DePuy Synthes (Johnson & Johnson), Zimmer Biomet Holdings, Inc., Smith & Nephew PLC, Medtronic PLC, Aesculap, Inc. (B. Braun Melsungen AG), DJO Global (Enovis Corporation), Ossur Hf., Acumed LLC (Colson Medical, Inc.) and Arthrex, Inc.
Recent Strategies Deployed in Upper Extremity Implants Market
Partnerships, Collaborations and Agreements:
May-2023: Zimmer Biomet took over Ossis, a maker 3D-printed orthopaedic implant. This acquisition would aim to build out their partnership and broadening Zimmer Biomet's orthopedic suite with the addition of Ossis' personalized implants.
Feb-2023: Zimmer Biomet Holdings, Inc. acquired Embody, Inc., a medical device company focused on soft tissue healing. Under this acquisition, Zimmer Biomet strengthens its growing Sports Medicine suite and supports continued business transformation.
Jul-2022: Acumed acquired ExsoMed, a provider of advanced solutions for hand surgery. This acquisition of ExsoMed, whose products support an intramedullary approach to treat hand fractures, increase Acumed's complete suite of upper extremity solutions for easy to complex injuries.
Jan-2021: DJO, LLC completed the acquisition of Trilliant Surgical®, a national provider of foot and ankle orthopedic implants. Following this acquisition, Trilliant Surgical's major product technologies and clinical efficacy supports DJO's focused development into the adjacent high-growth US foot and ankle market.
Jan-2021: Smith+Nephew completed the acquisition of the Extremity Orthopaedics business of Integra LifeSciences Holdings Corporation, a provider of broader and deeper solutions with an extensive soft tissue reconstruction offering. This acquisition would support Smith+Nephew's strategy to invest in higher growth segments. This would notably strengthen Smith+Nephew's extremities business by adding a combination of a focused sales channel, aligning with shoulder replacement and upper and lower extremities suite.
Product Launches and Product Expansions:
Oct-2021: DePuy Synthes introduced Variable Angle Locking Compression Plate, a 2.7 mm Clavicle Plate System, for the treatment of lateral, shaft and medial fractures for small, medium and large clavicles. The launched product provides plate shapes that shows the corelation between clavicle size and patient stature to match the bow and contour of the clavicle and contain a wide range of anatomic variability of the clavicle.
Aug-2021: Johnson & Johnson's DePuy Synthes division announced the launch of the Inhance shoulder system, a fully integrated system that includes both stemmed and stemless implants. The launch enables the surgeon to easily transform from the former to the latter at the time of procedure if required. Additionally, the product is designed to tackle a wide range of cases.
Geographical Expansions:
Jan-2022: Medtronic plc received a Japan's Ministry of Health, Labour and Welfare for the sale and reimbursement approval of the Micra™ AV Transcatheter Pacing System. This approval broadens the number of patients across Japan eligible to receive Micra TPS, the world's smallest pacemaker.
Approvals and Trials:
Aug-2022: Stryker opened a new facility in Ireland. The new high-tech facility is a 156,000-square-foot facility, which would reinforce the company's market position in additive manufacturing.
Market Segments covered in the Report:
By Material
By Type
By End-use
By Geography
Companies Profiled
Unique Offerings from KBV Research